StreetInsider.com News Articles

Form 3 Harmony Biosciences Hold For: Jul 16 Filed by: Mollichella Stephen M.

Wed, 22 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26801541.html

Form 3 Harmony Biosciences Hold For: Jul 16 Filed by: Mollichella Stephen M.

Wed, 22 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26801541.html

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

Tue, 21 Jul 2026 08:05:00 -0400

PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ226. It is recommended that you dial in at least 10 minutes prior to the call.

The

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

Tue, 21 Jul 2026 08:05:00 -0400

The

H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)

Mon, 20 Jul 2026 06:49:36 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $55.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY).

The analyst commented: "We are updating our model to reflect the surprisingly greater-than-expected demand that was the primary driver for the preannounced 2Q26 WAKIX revenue estimates beat. On July 16, Harmony preannounced (8-K) 2Q26 WAKIX net product revenues of approximately $261 million (vs. our prior $220.3 million estimate and the prior $242 million FactSet consensus); importantly, management attributed the beat to greater-than-expected demand in 2Q26. Notably, on Harmony's 1Q26 results conference call on May 7, management had indicated that the 1Q26

H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)

Fri, 17 Jul 2026 07:10:00 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $55.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY).

The analyst commented: 'Preliminary 2Q26 revenues exceed expectations and 2026 guidance positions WAKIX for clear blockbuster status—market reaction is overdone and creates a buying opportunity, in our view. This morning, Harmony preannounced (8-K) preliminary 2Q26 WAKIX net product revenue of approximately $261 million (vs. our prior $220.3 million estimate and the $242 million FactSet consensus)—a quarterly record—up 30% year-over-year (YoY) from $200.5 million in 2Q25, and 21% sequentially quarter-over-quarter (QoQ) from $215.4 million in 1Q26. Notably, Harmony reaffirmed full-year 2026 net

Form 8-K Harmony Biosciences Hold For: Jul 16

Thu, 16 Jul 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260716/26777173.html

Form 8-K Harmony Biosciences Hold For: Jul 16

Thu, 16 Jul 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260716/26777173.html

Harmony Biosciences posts record Q2 revenue, CFO steps down

Thu, 16 Jul 2026 08:30:26 -0400

Harmony Biosciences Holdings (NASDAQ: HRMY) reported preliminary, unaudited net product revenue of approximately $261 million for the second quarter of 2026 from its drug WAKIX (pitolisant), marking a 30% increase year over year and 21% growth compared to the first quarter of 2026, according to a company press release.

The Plymouth Meeting, Pa.-based pharmaceutical company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, citing first-half performance and current business trends.

"Demand remains strong, our commercial execution continues to deliver results and, based on our performance through the first half of the year, we remain confident in

Harmony Biosciences posts record Q2 revenue, CFO steps down

Thu, 16 Jul 2026 08:30:26 -0400

"Demand remains strong, our commercial execution continues to deliver results and, based on our performance through the first half of the year, we remain confident in

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Thu, 16 Jul 2026 08:30:00 -0400

WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026

Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion

Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a new quarterly revenue record for the Company and growth of 30% year over year and 21% growth for Q2 over Q1. These results underscore

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Thu, 16 Jul 2026 08:30:00 -0400

WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026

Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion

Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Thu, 16 Jul 2026 08:30:00 -0400

WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026

Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion

Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Thu, 16 Jul 2026 08:30:00 -0400

WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026

Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion

Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026

Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)

Wed, 08 Jul 2026 06:38:15 -0400

Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $50.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY).

The analyst commented: "Yesterday, the transcript from the 3-day bench trial between HRMY and AET Pharma, the last remaining ANDA filer against Wakix, was posted on PACER (case number 1:2023cv01286; please reach out to us for a copy). While we plan a deeper dive into the full ~850-page transcript with an IP expert in the near future, based on our initial analysis, in retrospect, price targets and ratings downgrades from other sell-side analysts that were seen immediately following the trial's conclusion in

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Thu, 02 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260702/26727650.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Thu, 02 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260702/26727650.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Tue, 30 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260630/26713502.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Tue, 30 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260630/26713502.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Fri, 26 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260626/26699032.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Fri, 26 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260626/26699032.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Wed, 24 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260624/26685784.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Wed, 24 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260624/26685784.html

H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)

Wed, 24 Jun 2026 06:43:40 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $55.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY).

The analyst commented: "SLEEP 2026 reinforces Harmony’s pitolisant lifecycle strategy, pitolisant high dose (HD; HBS-301) and pitolisant gastro-resistant (GR; HBS-201). From June 14–17, Harmony presented six posters across narcolepsy and idiopathic hypersomnia (IH), spanning WAKIX (pitolisant) subgroup efficacy use in narcolepsy, pitolisant use in IH, Phase 3 trial designs for HBS-301, HBS-201 dosing optimization, and the patient experience of fatigue in narcolepsy. We view the updates as incrementally positive, including: (1) pooled randomized data reinforced WAKIX’s consistent efficacy across broad patient

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Thu, 11 Jun 2026 15:03:00 -0400

Agreement highlights Paragon’s ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions

CHICAGO--(BUSINESS WIRE)-- Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology companies that deliver important treatments to the patients who need them.

Emalex is another Paragon Biosciences-founded company built to develop a novel class of treatment for patients with central nervous system disorders, following in the footsteps of other successful Paragon companies such as Harmony Biosciences (NASDAQ: HRMY). Ecopipam, an investigational compound, was developed by Emalex for